Senior Director
JMI Laboratories
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Dee Shortridge, PhD, Senior Director, Microbiology and Diagnostics, JMI Laboratories
Dr. Dee Shortridge completed her PhD in Microbiology and Immunology at University of Colorado Health Sciences Center in Denver and completed a Clinical Postdoctoral Education Program fellowship at University of Washington in Seattle.
Dr. Shortridge began her antimicrobial research at Abbott Laboratories where she began work as a Research Scientist in the screening of new antibacterial compounds as well as doing research on the macrolide and quinolone resistance mechanisms of various organisms including Helicobacter pylori and Streptococcus pneumoniae. She then became responsible for the clinical microbiology of antimicrobial clinical treatment trials at Abbott. As Sr. Group Leader for Clinical Microbiology, she worked on the clinical development cethromycin and delafloxacin among other compounds, and the filing and subsequent approvals for clarithromycin treatment of H. pylori infections and cefdinir for pediatric respiratory infections.
Dr. Shortridge then moved to the position of Manager and then Director of R&D Microbiology at bioMerieux, Inc. for VITEK2 Systems, an automated instrument used by clinical laboratories to identify and determine antimicrobial susceptibility of clinical isolates. In that position, her primary role was leading the development of antimicrobial susceptibility testing assays for new drugs, redevelopment of existing assays, and support of manufacturing, and regulatory for VITEK2 products. She served on the editorial boards of Journal of Clinical Microbiology (2000-2008) and Antimicrobial Agents and Chemotherapy (2002-2014). Dee serves as an ad hoc reviewer for Journal of Clinical Microbiology and Antimicrobial Agents and Chemotherapy as well as other journals.
Dr. Shortridge joined JMI in 2016 as a Senior Director for Microbiology. In her current position, Dr. Shortridge is responsible for overseeing projects for new antibiotic development, surveillance, device development, and clinical trial studies. Dr. Shortridge has authored or coauthored more than 65 microbiology publications in peer reviewed journals.
